Get the Stockscreener App
2.195
1.13%
-0.025
Mersana Therapeutics Inc stock is traded at $2.195, with a volume of 16,295.
It is down -1.13% in the last 24 hours and up +4.52% over the past month.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
See More
Previous Close:
$2.22
Open:
$2.23
24h Volume:
16,295
Relative Volume:
0.02
Market Cap:
$273.63M
Revenue:
$36.86M
Net Income/Loss:
$-171.67M
P/E Ratio:
-1.076
EPS:
-2.04
Net Cash Flow:
$-171.05M
1W Performance:
-12.90%
1M Performance:
+4.52%
6M Performance:
-16.22%
1Y Performance:
+38.92%
1-Day Range:
$2.19
$2.29
1-Week Range:
$1.98
$2.61
52-Week Range:
$1.22
$6.2801
Mersana Therapeutics Inc Stock (MRSN) Company Profile
Name
Mersana Therapeutics Inc
Sector
Industry
Phone
617-498-0020
Address
840 MEMORIAL DRIVE, CAMBRIDGE
Compare MRSN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| MRSN | 2.19 | 273.63M | 36.86M | -171.67M | -171.05M | -2.04 |
| VRTX | 447.51 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 741.90 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.12 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.68 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.20 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-04-23 | Upgrade | Citigroup | Neutral → Buy |
| Jul-28-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-27-23 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-27-23 | Downgrade | Citigroup | Buy → Neutral |
| Jul-27-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-27-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-27-23 | Downgrade | Truist | Buy → Hold |
| Jul-27-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-16-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-15-23 | Initiated | Guggenheim | Buy |
| Mar-16-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-20-23 | Initiated | Citigroup | Buy |
| Nov-21-22 | Initiated | Truist | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Aug-30-21 | Initiated | H.C. Wainwright | Buy |
| Mar-31-21 | Initiated | Credit Suisse | Neutral |
| Dec-03-20 | Initiated | Stifel | Buy |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Apr-29-20 | Initiated | BTIG Research | Buy |
| Jan-21-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-11-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-14-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| May-08-18 | Initiated | Robert W. Baird | Outperform |
| Mar-19-18 | Downgrade | JP Morgan | Overweight → Neutral |
View All
Mersana Therapeutics Inc Stock (MRSN) Latest News
This Particular Biotech Stock Is Soaring On Two Key Announcements - MSN
Mersana Therapeutics (STU:0M4) Cyclically Adjusted Revenue per Share : €0.00 (As of Sep. 2024) - GuruFocus.com
Mersana Therapeutics Q3 2024 Earnings Preview - MSN
16,178 Shares in Mersana Therapeutics, Inc. (NASDAQ:MRSN) Acquired by US Bancorp DE - Defense World
Leerink Partnrs Issues Optimistic Estimate for MRSN Earnings - Defense World
Wedbush Predicts Stronger Earnings for Mersana Therapeutics - Defense World
Wedbush Expects Increased Earnings for Mersana Therapeutics - MarketBeat
FY2024 Earnings Estimate for MRSN Issued By Leerink Partnrs - MarketBeat
Mersana Therapeutics transferred with Buy rating at Citi - MSN
MRSN (Mersana Therapeutics) Short-Term Capital Lease Obliga - GuruFocus.com
Citi bullish on mersana stock ahead of XMT-1660 data catalyst - Investing.com
Mersana Therapeutics (NASDAQ:MRSN) Coverage Initiated at Citigroup - MarketBeat
MRSN (Mersana Therapeutics) Short-Term Debt : $8.33 Mil (As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Purchase Of Business : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) ROE % Adjusted to Book Value : -18.30% (As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Debt-to-Revenue : 3.52 (As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Change In Receivables : $-1.57 Mil (TTM As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Change In Prepaid Assets : $5.85 Mil (TTM As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Retained Earnings : $-869.94 Mil (As of Jun. 2024) - GuruFocus.com
Mersana Therapeutics Provides Business Update and Financial Results for Third Quarter 2024 - Defense World
MRSN (Mersana Therapeutics) Ending Cash Position : $59.48 Mil (As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Free Cash Flow : $-95.57 Mil (TTM As of Sep. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Capex-to-Operating-Cash-Flow : 0.00 (As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Cash Flow for Lease Financing : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Other Long-Term Liabilities : $0.02 Mil (As of Sep. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Long-Term Capital Lease Obligat - GuruFocus.com
MRSN (Mersana Therapeutics) Effect of Exchange Rate Changes : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Other Stockholders Equity : $-0.00 Mil (As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Issuance of Debt : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Net Income From Continuing Operations : $-104.77 Mil (TTM As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Cash Flow from Operations : $-132.56 Mil (TTM As of Jun. 2024) - GuruFocus.com
Balyasny Asset Management L.P. Acquires New Stake in Mersana The - GuruFocus.com
Earnings call: Mersana Therapeutics reports progress in ADC clinical trials - Investing.com India
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q3 2024 Earnings Call Transcript - Insider Monkey
Rivian, Mersana Therapeutics, MicroStrategy (MSTR) and Honest Company Among Strong Movers in Premarket Trades - TopNews India
Earnings call: Mersana Therapeutics reports progress in ADC clinical trials By Investing.com - Investing.com UK
Mersana Therapeutics Inc (MRSN) Q3 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Mersana Therapeutics Reports Q3 2024 Financial Results - TipRanks
Dow Jones Industrials Average (DOWI) QuotePress Release - The Globe and Mail
FANG Index (FGU25) Quote - The Globe and Mail
Mersana Therapeutics Shares Climb 23% After 3Q Results Beat Estimates - MarketWatch
Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Mersana Therapeutics (MRSN) Q3 2024 Earnings: EPS Loss of $0.09 Beats Estimates, Revenue Surges to $12.6M - GuruFocus.com
Mersana Therapeutics Reports Progress in Cancer Treatments - TipRanks
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results - GlobeNewswire
Mersana Therapeutics, Inc. Provides Business Update - Marketscreener.com
Earnings Preview For Mersana Therapeutics - Benzinga
Mersana Therapeutics presents new data on XMT-2056 - BioWorld Online
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives $6.00 Consensus Price Target from Brokerages - Defense World
Is Mersana Therapeutics (NASDAQ:MRSN) Using Debt Sensibly? - Simply Wall St
Brokerages Set Mersana Therapeutics, Inc. (NASDAQ:MRSN) Target Price at $6.00 - MarketBeat
Mersana Therapeutics Inc Stock (MRSN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):